Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

its primary endpoint at the end of the trial. Based on the DSMB decision, Eli Lilly and Company (Lilly) provided a US $10 million milestone payment to BioMS as part of the terms of the licensing and collaboration agreement. BioMS anticipates MAESTRO-01 will be completed in 2009 with results from the trial expected in the second half of this year. - MAESTRO-02: Eligible patients who have successfully completed MAESTRO-01 may choose to receive dirucotide on an un-blinded basis in this open-label follow-on study. To date, approximately 95% of the eligible patients who have successfully completed the MAESTRO-01 trial have enrolled in this follow-on study. - MAESTRO-03: Enrollment was initiated in June, 2007 and completed on August 1, 2008 for this pivotal U.S. phase III trial of approximately 510 SPMS patients at 67 sites across the U.S. To date, the DSMB has conducted three reviews of the data from this trial and recommended it continue. The next DSMB review is expected to take place in the second quarter of fiscal 2009. - MINDSET-01: MINDSET-01 was a randomized, double-blind study that recruited 218 relapsing-remitting MS patients at 24 trial sites in six countries across Europe. BioMS recently announced that the top line results of this exploratory study did not meet its primary endpoint of effecting annualized relapse rate or associated secondary magnetic resonance imaging (MRI) endpoints. Dirucotide did meet certain secondary endpoints related to the progression of the disease, including mean change from baseline in the EDSS and the MS Functional Composite (MSFC) score. Changes in EDSS and MSFC are primary and secondary outcomes in the ongoing phase III SP
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2
... Jointly Offer "Always on," Secure Solution For Mobile ... (Nasdaq:ADCT; www.adc.com ) and Network365 announced today a ... solution that helps generate additional revenue for mobile ... and trusted m-commerce transactions between operators, banks and ...
... a year in which Wisconsins real-time economy gained time ... news stories suggests the state is becoming a place where ... the champagne corks just yet: Wisconsin still has a long ... high-wage jobs as the state lost in the three-year manufacturing ...
... began requiring applicants to pay significant user fees when ... biologics. Such user fees have long been required for ... related to devices and biologics. In theory, user fees ... at what cost? User fees impose a significant financial ...
Cached Biology Technology:ADC and Network365 Team to Offer New End-to-End Mobile Payment System 2The (Tech) Economic Year in Review: Signs of Progress Amid Continuing Challenges 2The (Tech) Economic Year in Review: Signs of Progress Amid Continuing Challenges 3Fast Track: FDA User Fees: Do Faster Review Times Justify the Financial Burden? 2
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
(Date:10/16/2014)... Washington land managers have a new synthesis of recent ... mixed-conifer (MMC) forests in the two states. , ... Eastern Oregon and Washington: A Synthesis of the Relevant ... general technical report published by the U.S. Forest Service,s ... a request from managers for a synthesis of the ...
(Date:10/16/2014)... Syncytial Virus causes severe respiratory tract infections and ... year. Scientists at VIB and Ghent University have ... counteract this common virus infection. , Xavier ... that paves the way for the development of ... virus that causes suffering in numerous small children ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3New report synthesizes best available science on management of moist mixed-conifer forests 2New perspectives for development of an RSV vaccine 2
... now receive early notice of outbreaks of toxic algae ... activities along the coast. Weekly bulletins generated by the ... on observations from state partners, coupled with models, imagery ... weather systems. "Early notification of blooms is essential, ...
... SAN ANTONIO While endogenous estrogen (i.e., estrogen produced ... well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing estrogen ... reducing breast cancer risk, according to study results presented ... Symposium, held Dec. 8-12. "Our analysis suggests ...
... our understanding of human evolution have seen Walter and ... 2011 Gani Medal for Human Genetics by the Australian ... research in human genetics by early career researchers and ... Stephens Gani. Dr Oshlack, a senior research ...
Cached Biology News:Forecast system to warn of toxic algal outbreaks along Texas' shoreline 2Estrogen alone is effective for reducing breast cancer risk 2Genetic studies of human evolution win researcher 2011 Gani Medal 2
... The Helios gene gun system, 220-240 V, ... biomaterials into cells. This handheld device employs ... RNA-, and other biomaterial-coated gold microcarriers from ... cartridge directly into target cells. This system ...
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
... Digital Sight DS-L2 imaging controller is a ... DS-L1, and allows users to comfortably observe, ... DS-L2 controller features an 8.4 inch LCD ... variety of Nikon cameras including the DS-Fi1 ...
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Biology Products: